ACE inhibitors and end-organ damage in cardiovascular disease : alteration of the natural history of atherosclerosis. Prevention and regression. Erasmus medical workshop. Munich (DEU).
Follow-up angiography at 6 months was obtained in 94% of the 693 patients (778 successfully dilated coronary lesions) enrolled in the Multicenfer European Research trial with Cilazapril after Angioplasty to prevenT Transluminal Coronary Obstruction and Restenosis (MERCATOR) trial-a double-blind, placebo-controlled trial-to study the effects of cilazapril 5 mg b.i.d. on restenosis [defined as the mean loss in minimal luminal diameter during follow-up, assessed by an interpolated edge detection technique (coronary angiography analysis system)] and long-term clinical outcome.
No statistically significant difference could be detected between treatment and placebo groups with regard to clinical outcome or restenosis.
Mots-clés Pascal : Traitement instrumental, Chirurgie, Artère coronaire, Resténose, Voie percutanée, Facteur risque, Homme, Etude multicentrique, Randomisation, Etude double insu, Cilazapril, Chimiothérapie, Traitement, Prévention, Appareil circulatoire pathologie, Epidémiologie
Mots-clés Pascal anglais : Instrumentation therapy, Surgery, Coronary artery, Restenosis, Percutaneous route, Risk factor, Human, Multicenter study, Randomization, Double blind study, Chemotherapy, Treatment, Prevention, Cardiovascular disease, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0084832
Code Inist : 002B26E. Création : 199406.